<DOC>
	<DOCNO>NCT03057418</DOCNO>
	<brief_summary>This open-label study safety , tolerability , pharmacokinetics pharmacodynamics Auriхim multiple dos patient recurrent/ refractory В-cell , CD20-positive non-Hodgkin lymphoma low tumor grade follicular lymphoma , well patient non-treated В-cell , CD20-positive non-Hodgkin lymphoma low tumor grade . The study carry 4-6 Russian Belarussian site . The study consist screening period , induction ( obligatory ) phase support ( non-obligatory ) phase investigational therapy post-treatment follow-up period .</brief_summary>
	<brief_title>Open-label Study Safety , Tolerability , Pharmacokinetics Pharmacodynamics Auriхim</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<criteria>To participate clinical study , patient must comply follow criterion : 1 . Signed patient 's information sheet informed consent form 2 . Males female age ≥ 18 year 3 . The expected survival time le 6 month , need urgent intervention eliminate lifethreatening complication 4 . Histologically clinically confirm screen diagnosis Вcell , CD20positive nonHodgkin lymphoma low tumor grade follicular lymphoma , accord WHO 's ( World Health Organization ) classification year 2008 , namely : Follicular lymphoma , cytological stage 1 , 2 3a Lymphoma small lymphocyte ( Small Lymphocytic Lymphoma ) number peripheral blood lymphocyte &lt; 5,000/mсl Lymphoplasmacytic lymphoma , include Waldenstrom 's macroglobulinemia paraprotein meaning ( IgM ) &gt; 2,0 g/l Extranodal marginal zone Bcell lymphoma MALTtype Nodal marginal zone Bcell lymphoma ( ± monocytoid В lymphocytes ) Lymphoma lien marginal zone cell . 5 . Patients receive therapy main disease , disease recurrence , refractivity previous therapy 6 . II , III IV disease stage accord Ann Arbor 's classification indication immunotherapy , Investigator 's opinion 7 . The patient must least one 2view measurable lesion ( size long axis &gt; 1,5 cm size short axis &gt; 1,0 cm , measure mean CT scanner ) , undergo radiotherapy past appear course previous treatment . 8 . Patients must ECOG status 0 2 9 . Requirements laboratory parameter determine : Hematology : Absolute neutrophil count : Platelets : Hemoglobin : ≥ 1500/mm3 ( 1.5 x 109 cells/L ) 100 000/mm3 ( 100 x 109 cells/L ) 8.0 g/dl Liver function : Total bilirubin : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) : ≤ 1.5 x ULN ≤ 2.5 x ULN Renal function : GFR ( accord CocroftGolt formula ) : &gt; 30 ml/min . 10 . The patient must practice effective method birth control whole period study 12 month last administration investigational product . The patient consider ineligible study case he/she criterion list : 1 . Chronic lymphocytic leukemia 2 . CNS invasion history ( lymphoma CNS lymphomatous meningitis ) 3 . Treatment chemotherapeutic agent radiotherapy within 4 week screen , treatment nitrosourea mitomycin C within 6 week screen presence ongoing toxicity ≥ II grade accord CTCAE , related prior therapy ( exclude alopecia ) 4 . Prior treatment MAb ( monoclonal antibody ) within 3 month screen 5 . Concomitant immunosupressive therapy systemic treatment corticosteroid moment screening . 6 . Clinically significant cardiovascular disease : Myocardial infarction within 6 month screen Unstable angina within 3 month screen Congestive heart failure Class III IV accord New York Heart Association ( NYHA ) criteria Clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation ) QTc interval &gt; 460 m ( ECG ) ( calculate accord Fredericia formula ) , diagnosis long QTc syndrome Ejection fraction leave ventricle ≤ 50 % ( EchoCG ) Hypotension ( systolic arterial blood pressure &lt; 86 mm mercury ) bradycardia heart rate &lt; 50 beat per min. , except cause medication ( e.g . betablockers ) Uncontrolled arterial hypertension ( systolic arterial blood pressure &gt; 170 mm mercury diastolic arterial blood pressure &gt; 105 mm mercury ) 7 . Peripheral neuropathy ≥ III severity level 8 . Primary secondary immunodeficiency history 9 . Presence antibody human immunodeficiency virus ( HIV ) , hepatitis С virus ( HCV ) , active hepatitis B 10 . Tuberculosis last 5 year positive result Quantiferon test 11 . Active infection within 4 week screen 12 . Surgical interference ( exclude biopsy lymphatic node ) within 4 week screen 13 . History malignancy exception cervical carcinoma situ skin basalcell carcinoma , undergone surgical removal treatment within ≥ 5 year screen 14 . Uncontrolled concomitant disease condition , include mental social , , Investigator 's opinion , may prevent patient participation study . 15 . Hypersensitivity medicinal agent use study , compound murine protein , well significant , Investigator 's opinion , allergic reaction history 16 . Participation clinical study administration investigational product within 30 day screen , ongoing adverse reaction investigational product 17 . Drug alcohol abuse moment screen past , , Investigator 's opinion , make patient unsuitable participation study . 18 . Pregnant lactate woman , woman plan get pregnant clinical study ; woman childbearing potential ( sterile postmenopause le 2 year ) practice effective method birth control . Effective method birth control include usage : oral , injectable transdermal contraceptive condom diaphragm ( barrier method ) spermicide , intrauterine device 19 . Inability read write , unwillingness understand comply procedure study protocol , well concomitant medical serious mental condition , make patient unsuitable participation clinical study , limit validity inform consent receipt may affect patient 's ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>